A revised prognostic model for patients with acute myeloid leukemia and first relapse.

ABSTRACT:

Abstract

Most patients with acute myeloid leukemia (AML) may obtain remission upon induction chemotherapy, but relapse is frequent and associated with poor survival. Previous prognostic models for outcomes after relapse lacked analysis of comprehensive molecular data. A validated prognostic model integrating clinical, cytogenetic, and molecular variables may support treatment decisions. We studied 943 patients with AML who relapsed after intensive induction treatment in a development cohort (HOVON-SAKK). A random survival forest algorithm was used to evaluate the association of clinical parameters, cytogenetic abnormalities, and molecular variables at diagnosis with overall survival (OS). Relapsing patients (n = 377) who were enrolled in the NCRI-AML18 trial were used for validatio

SUBMITTER: van der Maas NG 

PROVIDER: S-EPMC12329292 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature